The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients
Abstract
Introduction Abbreviations used in this article: aCL, anticardiolipin antibodies, ANA, antinuclear antibodies, anti-dsDNA, anti-dsDNA antibodies, aPL, antiphospholipid antibodies, APS, antiphospholipid syndrome, ARDS, acute respiratory distress syndrome, CSF, cerebrospinal fluid, CT, computed tomography, DIC, disseminated intravascular coagulation, ECG, electrocardiogram, ENA, extractable nuclear antigen antibodies, ESR, erythrocyte sedimentation rate, HPF, high power field, INR, international normalized ratio, LA, lupus anticoagulant, PT, prothrombin time, PTT, partial thromboplastin time, SLE, systemic lupus erythematosus, TTP, thrombotic thrombocytopenic purpura, WBC, white blood count The antiphospholipid syndrome (APS), originally defined as the combination of venous or arterial thrombotic events, recurrent fetal loss, and, frequently, a moderate thrombocytopenia in association with antiphospholipid antibodies (aPL), was subsequently greatly expanded to include diverse conditions, for example, heart valve lesions, adrenal insufficiency, and pulmonary syndromes such as acute respiratory distress syndrome (ARDS), “capillaritis,” and pulmonary alveolar hemorrhage, among others (16,17). It was then realized that several “microangiopathic syndromes” also existed, as opposed to large vessel occlusive disease. Single organs, such as the kidneys, heart, skin, and brain, have been affected by this “thrombotic microangiopathy” in the context of the “classic” or “simple” APS. The temporal occurrence of thrombotic events in patients with this classic APS usually extends over months or years. In 1992, the existence of a new “subset” was described in which multiple vascular occlusive events, usually affecting small vessels supplying organs and presenting over a short period of time, were the outstanding features. This subset was termed the “catastrophic” APS. Although large vessel occlusions were also present, their prevalence did not in any way approach that in patients with the classic APS. The occlusions occurred over days to several weeks, and more than 50% of patients usually succumbed despite seemingly adequate therapy, including anticoagulation, steroids, etc. (6). In 1998, a comprehensive review article with the clinical and laboratory description of 50 such patients was published (8). In the present paper we describe the clinical and serologic features of the largest series of patients with catastrophic APS hitherto reported, including 30 new cases from interested physicians in many different countries, as well as a comprehensive literature review of 50 additional recently published case reports with this syndrome. This new series, comprising a total of 80 patients, enables us to analyze further and clarify not only the clinical importance of this syndrome, but also its pathogenesis. Methods We undertook a computer-assisted (MEDLINE, National Library of Medicine, Bethesda, MD) search of the literature to locate all cases of catastrophic APS published in English, Spanish, and French from 1996 (when the previous comprehensive review series of catastrophic APS was completed [8]) through 2000 (keywords:lupus anticoagulant, coagulation inhibitor, lupus inhibitor, anticardiolipin, cardiolipin, anticardiolipin antibody, antiphospholipid, phospholipid, antiphospholipid antibody, antiphospholipid syndrome, catastrophic antiphospholipid syndrome). We also retrospectively analyzed several original cases categorized as having catastrophic APS that were not included in the previous series. Additionally, the bibliographies of all articles were systematically scanned for references not identified in the initial search. Patients were considered as having catastrophic APS if they presented an acutely devastating APS with multiple organ involvement, as previously defined (6). Data from these patients were summarized using a standardized data form, including sex, age, diagnosis of the underlying condition, precipitating factors, main thrombotic clinical manifestations, immunologic features, treatment, and evolution. Thirty new and previously unpublished cases (14 patients from the European Union, 8 from the United States, and 8 from other countries) were added to the literature review. The bilateral Fisher exact test was used for statistics. Case Reports The most relevant data of the 80 case reports are described in Tables 1 (general clinical manifestations), 2 (thrombotic manifestations and outcome), and 3 (laboratory findings). Twelve illustrative case reports are described in detail.TABLE 1: General clinical manifestations of 80 patients with catastrophic APSTABLE 1: —ContinuedTABLE 2: Thrombotic clinical manifestations of patients at the time of catastrophic APSTABLE 2: —ContinuedTABLE 2: —ContinuedTABLE 3: Laboratory findings of patients with catastrophic APSTABLE 3: —ContinuedCase 1 The patient was a 42-year-old Chinese female secretary with psoriasis of 2 years’ duration, and systemic lupus erythematosus (SLE) diagnose
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients
Asherson, R. A., Cervera, R., Piette, J.-C., Font, J., Lie, J. T., Burcoglu, A., Lim, K., Muñoz-Rodríguez, F. J., Levy, R. A., Boué, F., et al. (1998) · Medicine · doi:10.1097/00005792-199805000-00005 · Cited by 544
Self-citationPrevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8
Sekido, N., Mukaida, N., Harada, A., Nakanishi, I., Watanabe, Y., & Matsushima, K. (1993) · Nature · doi:10.1038/365654a0 · Cited by 514
Adult respiratory distress syndrome profiles by computed tomography
Gattinoni, L., Presenti, A., Torresin, A., Baglioni, S., Rivolta, M., Rossi, F., Scarani, F., Marcolin, R., & Cappelletti, G. (1986) · Journal of Thoracic Imaging · doi:10.1097/00005382-198607000-00005 · Cited by 297
Bilateral Massive Adrenal Hemorrhage: Early Recognition and Treatment
Rao, R. H., Vagnucci, A. H., & Amico, J. A. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-3-227 · Cited by 252
Culmination of an era in research on the acute respiratory distress syndrome.
Tobin, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421808 · Cited by 177
Thrombotic Storm: When Thrombosis Begets Thrombosis
Kitchens, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00061-8 · Cited by 169
Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides
Gharavi, E. E., Chaimovich, H., Cucurull, E., Celli, C. M., Tang, H., Wilson, W. A., & Gharavi, A. E. (1999) · Lupus · doi:10.1177/096120339900800607 · Cited by 109
Antiphospholipid Syndrome Associated with Cytomegalovirus Infection: Case Report and Review
Labarca, J. A., Ricardo Rabagliati, B., Radrigán, F., Rojas, P. P., Perez, C. M., Marcela Ferrés, G., Acuña, G., & Bertín, P. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.197 · Cited by 106
Petrovas, C., Vlachoyiannopoulos, P. G., Kordossis, T., & Moutsopoulos, H. Μ. (1999) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0324 · Cited by 103
Poliak, S., Mor, F., Conlon, P. J., Wong, T., LING, N. C., Rivier, J., Vale, W., & Steinman, L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.12.5751 · Cited by 86
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Self-citationAsherson, R. A., Cervera, R., de Groot, P. G., Erkan, D., Boffa, M.-C., Piette, J.-C., Khamashta, M. A., Shoenfeld, Y., & Catastrophic Antiphospholipid Syndrome Registry Project Group (2003) · Lupus · doi:10.1191/0961203303lu394oa · Cited by 865
Self-citationManson, J. J., & Rahman, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-6 · Cited by 605
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Metadata
- Authors
- ASHERSON, R. A., CERVERA, R., PIETTE, J.-C., SHOENFELD, Y., ESPINOSA, G., PETRI, M. A., LIM, E., LAU, T. C., GURJAL, A., JEDRYKA-GÓRAL, A., CHWALINSKA-SADOWSKA, H., DIBNER, R. J., ROJAS-RODRÍGUEZ, J., GARCÍA-CARRASCO, M., GRANDONE, J. T., PARKE, A. L., BARBOSA, P., VASCONCELOS, C., RAMOS-CASALS, M., FONT, J., & INGELMO, M.
- Venue
- Medicine
- Published
- 2001-11
- Volume
- 80
- Issue
- 6
- Pages
- 355-377
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2084803912
- Cited by
- 388
- References
- 32
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients. https://app.cochat.ai/papers/10.1097/00005792-200111000-00002
- The paper
- ASHERSON, R. A., CERVERA, R., PIETTE, J.-C., SHOENFELD, Y., ESPINOSA, G., PETRI, M. A., LIM, E., LAU, T. C., GURJAL, A., JEDRYKA-GÓRAL, A., CHWALINSKA-SADOWSKA, H., DIBNER, R. J., ROJAS-RODRÍGUEZ, J., GARCÍA-CARRASCO, M., GRANDONE, J. T., PARKE, A. L., BARBOSA, P., VASCONCELOS, C., RAMOS-CASALS, M., . . . INGELMO, M. (2001). Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients. Medicine. https://doi.org/10.1097/00005792-200111000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.